Dr. Noah Biotech’s phrase 1 drug candidate for stroke patients submitted for an IND application as the first example developed by AI
New combinatory phrase 1 drug candidate, NDC-002, that helps reduce neuroinflammation and stimulate neuronal differentiation
Dr. Noah Biotech announced that it submitted an Investigational New Drug (IND) application to the Korea Food and Drug Administration (KFDA) to demonstrate its new phrase 1 drug candidate, ‘NDC-002’ that helps recover from stroke on July 22.
The company said if it obtains an approval of the IND application, ‘NDC-002’ would be regarded as the first example of the new drug candidate developed by AI in Korea.
Based on multiple mechanisms, the NDC-002 has been developed as a new combinatory drug with two agents that help reduces brain damages and accelerate the differentiation of damaged neuronal cells by reducing neurological inflammation for the recovery the side effects of stroke. It is the very first drug candidate developed within the ARK platform of Dr. Noah Biotech.
Dr. Noah Biotech has developed ‘NDC-002’ within the ARK platform. By applying the artificial intelligence system, it is designed to improve the efficiency of drugs in stages including the selection of new drug candidates, evaluation of the drugs' effectiveness and prediction of any side effects. In addition, when new drug candidates are identified, they develop new combinatory drugs within the VLab and CombiNet system that could create synergistic effects rather than single new drugs. The NeuroRG system is used to verify the effectiveness of new drug candidates by analyzing the changes of nerve cells presented with images in the research institute. Then, the side effects of new combinatory drugs are identified within the CombiRisk system just before they are involved in the final stage of the clinical trial.
Stroke is one of the leading causes of death not only in Korea, but also around the world. It is important for patients to visit the hospital within 6 hours, which is often called the golden hour, and get preliminary treatment such as thrombectomy and hematoma evacuation. However, in most cases, delayed hospital visits trigger delayed diagnosis and treatment of the disease. Furthermore, there are not much approved treatment options that help their recovery except for the rehabilitation treatment.
Jihyun Lee, CEO of Dr. Noah Biotech, said, “We have focused on the development of our own process covering from discovery to development of new drugs” and “based on our previous experiences, we will plan to establish our pipeline for neurological diseases in an active and systematic manner.”
She also stressed that the company plans to finalize the investment in series B this year. She said that by conducting more than two annual global clinical trials from 2022, we are going to transfer our technologies sequentially and develop new ones on their own to become an AI leading pharmaceutical company.
By Journalist Seo, Yoon-seok of Bio Spectator email@example.com